Differences in the Expression of Endogenous Efflux Transporters in MDR1-transfected Versus Wildtype Cell Lines Affect P-glycoprotein Mediated Drug Transport

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2010 Jul 2

PMID 20590635

Citations 26

Authors

Konstantin Kuteykin-Teplyakov

Carlos Luna-Tortos

Kamila Ambroziak

Wolfgang Loscher

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: P-glycoprotein (Pgp) efflux assays are widely used to identify Pgp substrates. The kidney cell lines Madin-Darby canine kidney (MDCK)-II and LLC-PK1, transfected with human MDR1 (ABCB1) are used to provide recombinant models of drug transport. Endogenous transporters in these cells may contribute to the activities of recombinant transporters, so that drug transport in MDR1-transfected cells is often corrected for the transport obtained in parental (wildtype) cells. However, expression of endogenous transporters may vary between transfected and wildtype cells, so that this correction may cause erroneous data. Here, we have measured the expression of endogenous efflux transporters in transfected and wildtype MDCK-II or LLC cells and the consequences for Pgp-mediated drug transport.

Experimental Approach: Using quantitative real-time RT-PCR, we determined the expression of endogenous Mdr1 mRNA and other efflux transporters in wildtype and MDR1-transfected MDCK-II and LLC cells. Transcellular transport was measured with the test substrate vinblastine.

Key Results: In MDR1-transfected MDCK cells, expression of endogenous (canine) Mdr1 and Mrp2 (Abcc2) mRNA was markedly lower than in wildtype cells, whereas MDR1-transfected LLC cells exhibited comparable Mdr1 but strikingly higher Mrp2 mRNA levels than wildtype cells. As a consequence, transport of vinblastine by human Pgp in efflux experiments was markedly underestimated when transport in MDR1-transfected MDCK cells was corrected for transport obtained in wildtype cells. This problem did not occur in LLC cells.

Conclusions And Implications: Differences in the expression of endogenous efflux transporters between transfected and wildtype MDCK cells provide a potential bias for in vitro studies on Pgp-mediated drug transport.

Citing Articles

Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?.

van Valkengoed D, Hirasawa M, Rottschafer V, de Lange E J Pharmacokinet Pharmacodyn. 2025; 52(2):16.

PMID: 39921770 PMC: 11807079. DOI: 10.1007/s10928-025-09963-w.

Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?.

Gulave B, Lesmana A, de Lange E, van Hasselt J J Pharmacokinet Pharmacodyn. 2025; 52(1):11.

PMID: 39776000 PMC: 11706904. DOI: 10.1007/s10928-024-09957-0.

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19.

Assmus F, Driouich J, Abdelnabi R, Vangeel L, Touret F, Adehin A Microorganisms. 2022; 10(8).

PMID: 36014057 PMC: 9460261. DOI: 10.3390/microorganisms10081639.

Generation of Knockout and Transgenic Zebrafish to Characterize Abcc4 Functions in Detoxification and Efflux of Lead.

Lu X, Long Y, Li X, Zhang L, Li Q, Wen H Int J Mol Sci. 2021; 22(4).

PMID: 33669601 PMC: 7923114. DOI: 10.3390/ijms22042054.

Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).

Nicklisch S, Hamdoun A FEBS Lett. 2020; 594(23):4158-4185.

PMID: 33222203 PMC: 8112642. DOI: 10.1002/1873-3468.14005.

References

Baltes S, Gastens A, Fedrowitz M, Potschka H, Kaever V, Loscher W . Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2006; 52(2):333-46. DOI: 10.1016/j.neuropharm.2006.07.038. View

Chen Z, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T . Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999; 56(6):1219-28. DOI: 10.1124/mol.56.6.1219. View

Rautio J, Humphreys J, Webster L, Balakrishnan A, Keogh J, Kunta J . In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006; 34(5):786-92. DOI: 10.1124/dmd.105.008615. View

Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A . Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm. 2008; 356(1-2):12-8. DOI: 10.1016/j.ijpharm.2007.12.024. View

Allen J, van Loevezijn A, Lakhai J, van der Valk M, van Tellingen O, Reid G . Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002; 1(6):417-25. View

Borst P, de Wolf C, van de Wetering K . Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2006; 453(5):661-73. DOI: 10.1007/s00424-006-0054-9. View

Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J . Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003; 46(9):1716-25. DOI: 10.1021/jm021012t. View

Borst P, Elferink R . Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537-92. DOI: 10.1146/annurev.biochem.71.102301.093055. View

Kuhnle M, Egger M, Muller C, Mahringer A, Bernhardt G, Fricker G . Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem. 2009; 52(4):1190-7. DOI: 10.1021/jm8013822. View

10.

Jin H, Di L . Permeability--in vitro assays for assessing drug transporter activity. Curr Drug Metab. 2008; 9(9):911-20. DOI: 10.2174/138920008786485056. View

11.

Giri N, Agarwal S, Shaik N, Pan G, Chen Y, Elmquist W . Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos. 2008; 37(3):560-70. PMC: 2680510. DOI: 10.1124/dmd.108.022046. View

12.

Matsson P, Pedersen J, Norinder U, Bergstrom C, Artursson P . Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res. 2009; 26(8):1816-31. DOI: 10.1007/s11095-009-9896-0. View

13.

Thuerauf N, Fromm M . The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci. 2006; 256(5):281-6. DOI: 10.1007/s00406-006-0662-6. View

14.

Taub M, Podila L, Ely D, Almeida I . Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos. 2005; 33(11):1679-87. DOI: 10.1124/dmd.105.005421. View

15.

Horio M, Chin K, Currier S, Goldenberg S, Williams C, Pastan I . Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem. 1989; 264(25):14880-4. View

16.

Flanagan S, Cummins C, Susanto M, Liu X, Takahashi L, Benet L . Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002; 64(3):126-34. DOI: 10.1159/000056161. View

17.

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

18.

Polli J, Wring S, Humphreys J, Huang L, Morgan J, Webster L . Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001; 299(2):620-8. View

19.

Lloyd C, Schevzov G, Gunning P . Transfection of nonmuscle beta- and gamma-actin genes into myoblasts elicits different feedback regulatory responses from endogenous actin genes. J Cell Biol. 1992; 117(4):787-97. PMC: 2289461. DOI: 10.1083/jcb.117.4.787. View

20.

Yamazaki M, Neway W, Ohe T, Chen I, Rowe J, Hochman J . In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001; 296(3):723-35. View